Take­da wins pri­or­i­ty re­view for $400M col­orec­tal can­cer drug, li­censed from Hutchmed in Jan­u­ary

Take­da and Hutchmed scored a pri­or­i­ty re­view Thurs­day af­ter­noon for a col­orec­tal can­cer drug, the com­pa­nies an­nounced.

The ex­per­i­men­tal drug in ques­tion is fruquin­tinib, pre­vi­ous­ly ap­proved in Chi­na in 2018 to treat metasta­t­ic col­orec­tal can­cer. Take­da and Hutchmed are aim­ing to bring fruquin­tinib to the US and oth­er coun­tries out­side Chi­na in the same in­di­ca­tion, and the FDA set its de­ci­sion date for Nov. 30 of this year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN